Plus Therapeutics, Inc. (PSTV) announced on March 31, 2026 that it will implement a 1‑for‑25 reverse stock split, with the split becoming effective on April 2, 2026.
The reverse split will consolidate 25 shares of the company’s common stock into one share, reducing the number of outstanding shares and raising the per‑share price. The move is intended to bring the company into compliance with Nasdaq’s minimum bid‑price rule, which requires listed securities to maintain a bid price of at least $1.00 per share. PSTV has traded below $1.00 for extended periods, prompting the need for a corporate action to avoid potential delisting.
This corporate action is material because it directly affects the company’s share structure and its ability to remain listed on Nasdaq. While the announcement does not provide additional financial details or management commentary, it signals the company’s intent to preserve liquidity and maintain its exchange listing.
Investors should monitor subsequent disclosures for further information on the company’s financial position and future plans following the reverse split.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.